Hikma and Dr. Reddy's Laboratories have urged the US Supreme Court to deny certiorari review of a US Court of Appeals for the Federal Circuit decision affirming as invalid six patents shielding Amarin’s Vascepa (icosapent ethyl), insisting that it stems from a “fact-intensive” district court ruling “that applies settled obviousness precedent, breaks no new ground, and raises no question of any importance beyond Amarin’s patents.”
Just over a year ago, in a decision that took the market by surprise, Nevada district court judge Miranda Du...
